SEC Tracker
Get the app

ArriVent BioPharma AVBP

ArriVent BioPharma announces leadership change

ArriVent BioPharma (AVBP) filed an 8-K with the SEC on Nov 9, 2026, 4:06 pm ET. Source: the filing on SEC EDGAR.

Item 2.02 Reports results, Item 5.02 Executive or director change

Form
8-K
Filed
Importance
Major
  1. Dr. Stuart Lutzker will retire as President, R&D and director on Dec 1, 2026
  2. $428,438.21 retirement payment to Dr. Lutzker
  3. Dr. Priti Patel to lead R&D after Dec 1, 2026

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Get the appView on EDGAR

Get an email when ArriVent BioPharma files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Data on this page was fetched . The filing on SEC.gov is the record.